Return
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer (vol 394, pg 845, 2026)
L
P
S
H
B
J
P
DOI:10.1056/NEJMx260006.png)
Abstract
En
Journal
IF:
78.5
Papers:
2.7W
Citations:
39.7W
Organization
No organization information available
